Upgrade to BuyandBill.com Pro to access this report and the complete suite of analytics tools.
| Manufacturer ▼ | Drug Name | Indication | Stage | Status | Route of Administration | Drug Class |
|---|---|---|---|---|---|---|
| Hoth Therapeutics Inc. | HT-001 - (CLEER-001) | EGFRI-induced skin toxicity | Phase 2a | Data Released | Topical | Oncology |
| Hoth Therapeutics Inc. | HT-001 | Non-small cell lung cancer (NSCLC), pancreatic cancer, colorectal cancer, squamous-cell carcinoma of the head and neck, and breast cancer | Phase 2a | Topical | Oncology | |
| Humacyte Inc. | Vascular Tissue Constructs (HAV) | Dialysis (AV Access) | Phase 3 | Ongoing | Implantation | N/A |
| Humacyte Inc. | ATEV - (V007) | Acellular tissue engineered vessel (ATEV) in arteriovenous access for patients with end-stage renal disease. | Phase 3 | Data Released | oral | Orthopedic |
| Humanigen Inc. | Lenzilumab - (ACTIV-5/BET-B) | COVID-19 | Phase 2/3 | Intravenous | COVID-19 | |
| Humanigen Inc. | Lenzilumab - (RATinG) | Acute Graft versus Host Disease (GvHD) | Phase 2/3 | Intravenous | Immunosuppressant | |
| Humanigen Inc. | Lenzilumab | COVID-19 | Phase 3 | Intravenous | COVID-19 | |
| Humanigen Inc. | Lenzilumab - (PREACH-M) | Chronic myelomonocytic leukemia (CMML) | Phase 2 | Intravenous | Oncology |
